BRAF and melanoma: At the same time, advances in the understanding of aberrant molecular pathways in melanoma allowed for the development of selective inhibitors of mutated BRAF kinase.18 The year 2011 was one of monumental progress in the field as both ipilimumab and the BRAF inhibitor vemurafenib were approved for the treatment of advanced melanoma, ushering in an era of great hope for patients with this devastating illness.